Lost in Translation: Animal Models and Clinical Trials in Cancer Treatment

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2014 Feb 4

PMID 24489990

Citations 552

Authors

Isabella Wy Mak

Nathan Evaniew

Michelle Ghert

Affiliations

Soon will be listed here.

Abstract

Due to practical and ethical concerns associated with human experimentation, animal models have been essential in cancer research. However, the average rate of successful translation from animal models to clinical cancer trials is less than 8%. Animal models are limited in their ability to mimic the extremely complex process of human carcinogenesis, physiology and progression. Therefore the safety and efficacy identified in animal studies is generally not translated to human trials. Animal models can serve as an important source of in vivo information, but alternative translational approaches have emerged that may eventually replace the link between in vitro studies and clinical applications. This review summarizes the current state of animal model translation to clinical practice, and offers some explanations for the general lack of success in this process. In addition, some alternative strategies to the classic in vivo approach are discussed.

Citing Articles

Lipidomics reveals cell specific changes during pluripotent differentiation to neural and mesodermal lineages.

Odenkirk M, Jostes H, Francis K, Baker E Mol Omics. 2025; .

PMID: 40078081 PMC: 11904469. DOI: 10.1039/d4mo00261j.

Agent-based modeling of cellular dynamics in adoptive cell therapy.

Wang Y, Casarin S, Daher M, Mohanty V, Dede M, Shanley M bioRxiv. 2025; .

PMID: 40027823 PMC: 11870559. DOI: 10.1101/2025.02.17.638701.

Association between apical periodontitis and brain inflammation: a systematic review from animals and human studies.

da Conceicao Francisquini J, Toro L, Azevedo R, Tessarin G Odontology. 2025; .

PMID: 40011389 DOI: 10.1007/s10266-025-01069-6.

Sesquiterpene Lactones as Promising Phytochemicals to Cease Metastatic Propagation of Cancer.

Mehdikhani F, Hajimehdipoor H, Tansaz M, Maresca M, Rajabi S Biomolecules. 2025; 15(2).

PMID: 40001571 PMC: 11852507. DOI: 10.3390/biom15020268.

Evaluation of the Antioxidant, Antihyperglycemic, and Haemolytic Activities of Hydroalcoholic Extracts of Red and White Pithecellobium dulce Aril at Different Stages of Ripening.

Leyva-Lopez N, Cebreros-Vazquez C, Gomez-Saucedo V, Heredia J, Vega-Alvarez M, Colado-Velazquez J Plant Foods Hum Nutr. 2025; 80(1):74.

PMID: 39985710 DOI: 10.1007/s11130-025-01320-z.

References

Overall C, Kleifeld O . Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer. 2006; 94(7):941-6. PMC: 2361222. DOI: 10.1038/sj.bjc.6603043. View

Hackam D, Redelmeier D . Translation of research evidence from animals to humans. JAMA. 2006; 296(14):1731-2. DOI: 10.1001/jama.296.14.1731. View

Schuh J . Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol. 2004; 32 Suppl 1:53-66. DOI: 10.1080/01926230490424770. View

Chesler E, Wilson S, Lariviere W, Rodriguez-Zas S, Mogil J . Identification and ranking of genetic and laboratory environment factors influencing a behavioral trait, thermal nociception, via computational analysis of a large data archive. Neurosci Biobehav Rev. 2003; 26(8):907-23. DOI: 10.1016/s0149-7634(02)00103-3. View

Arrowsmith J . Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov. 2011; 10(2):87. DOI: 10.1038/nrd3375. View

Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K . Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs. 2010; 70(8):949-64. DOI: 10.2165/11318390-000000000-00000. View

Cavallo F, Offringa R, van der Burg S, Forni G, Melief C . Vaccination for treatment and prevention of cancer in animal models. Adv Immunol. 2006; 90:175-213. DOI: 10.1016/S0065-2776(06)90005-4. View

Ledford H . Translational research: 4 ways to fix the clinical trial. Nature. 2011; 477(7366):526-8. DOI: 10.1038/477526a. View

Vonderheide R, Nathanson K . Immunotherapy at large: the road to personalized cancer vaccines. Nat Med. 2013; 19(9):1098-100. DOI: 10.1038/nm.3317. View

10.

Seok J, Warren H, Cuenca A, Mindrinos M, Baker H, Xu W . Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013; 110(9):3507-12. PMC: 3587220. DOI: 10.1073/pnas.1222878110. View

11.

Curt G, Chabner B . One in five cancer clinical trials is published: a terrible symptom--what's the diagnosis?. Oncologist. 2008; 13(9):923-4. DOI: 10.1634/theoncologist.2008-0174. View

12.

Ogi C, Aruga A . Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology. 2013; 2(8):e26012. PMC: 3782518. DOI: 10.4161/onci.26012. View

13.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

14.

Cook N, Jodrell D, Tuveson D . Predictive in vivo animal models and translation to clinical trials. Drug Discov Today. 2012; 17(5-6):253-60. DOI: 10.1016/j.drudis.2012.02.003. View

15.

Matthews R . Medical progress depends on animal models - doesn't it?. J R Soc Med. 2008; 101(2):95-8. PMC: 2254450. DOI: 10.1258/jrsm.2007.070164. View

16.

Sena E, van der Worp H, Bath P, Howells D, Macleod M . Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol. 2010; 8(3):e1000344. PMC: 2846857. DOI: 10.1371/journal.pbio.1000344. View

17.

Yaddanapudi K, Mitchell R, Eaton J . Cancer vaccines: Looking to the future. Oncoimmunology. 2013; 2(3):e23403. PMC: 3661166. DOI: 10.4161/onci.23403. View

18.

Attarwala H . TGN1412: From Discovery to Disaster. J Young Pharm. 2010; 2(3):332-6. PMC: 2964774. DOI: 10.4103/0975-1483.66810. View

19.

Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P . Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2006; 334(7586):197. PMC: 1781970. DOI: 10.1136/bmj.39048.407928.BE. View

20.

Fingleton B . Matrix metalloproteinases as valid clinical targets. Curr Pharm Des. 2007; 13(3):333-46. DOI: 10.2174/138161207779313551. View